AzTrials
AzTrials

Ascaris LumbricoidesPhase 4ConWormNCT01379326

Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2

A Phase 4 study testing Mebendazole in people with Ascaris Lumbricoides and Ascaris Suum, run by University Ghent at 9 sites in 8 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Objectives: The overall objective is to monitor efficacy of mebendazole (MBZ) against Soil-Transmitted Helminths (STH). The primary objective is: (1) to monitor the efficacy a single dose 500 mg of mebendazole (MBZ) against Soil-Transmitted Helminths (STH) infections by means of Faecal Egg Count Reduction (FECR) and… Read more about this study

Who is it for?
Ages 4 to 18 years
What is being tested?
Mebendazole
Could I receive a placebo?
No, everyone receives an active treatment
How many people
250 participants
Where
9 sitesin 8 countries
Study dates
Dec 2011to Dec 2012
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

None listed.

Who cannot join

  • Subjects who are unable to provide a stool sample at follow-up
  • Subjects who are experiencing a severe concurrent medical condition
  • Subjects with diarrhea at first sampling

Trial locations and contacts

9 sites in 8 countries.

9 sites in 8 countries

Australia2 sites
  • Commonwealth Scientific and Industrial Research Organisation

    Brisbane

  • Queensland Institute for Medical Research, University of Queensland

    Herston QLD

Other trials in Australia

Argentina1 site
  • Fundacion Huesped

    Buenos Aires

Other trials in Argentina

Brazil1 site
  • Fundação Oswaldo Cruz

    Belo Horizonte

Other trials in Brazil

Cambodia1 site
  • Institut Pasteur in Cambodia, Clinical Pathology Unit

    Phnom Penh

Other trials in Cambodia

Cameroon1 site
  • University of Yaoundé I

    Yaoundé I

Other trials in Cameroon

Ethiopia1 site
  • College of Public Health and Medical Sciences, Jimma University

    Jimma

Other trials in Ethiopia

Tanzania1 site
  • Ivo de Carneri, Pemba Island

    Zanzibar

Other trials in Tanzania

Vietnam1 site
  • National Institute for Malariology, Parasitology and Entomology

    Hanoi

Other trials in Vietnam

About this study

Official title: The Efficacy of a Single-dose Mebendazole Against Soil-transmitted Helminths in School Children

Objectives:

The overall objective is to monitor efficacy of mebendazole (MBZ) against Soil-Transmitted Helminths (STH).

The primary objective is:

(1) to monitor the efficacy a single dose 500 mg of mebendazole (MBZ) against Soil-Transmitted Helminths (STH) infections by means of Faecal Egg Count Reduction (FECR) and Cure Rate (CR).

The secondary objectives are:

  1. to assess the occurrence of Necator americanus and Ancylostoma duodenal.
  2. to assess the occurrence of β-tubulin mutations related to resistance before and after drug administration.
  3. to evaluate the role of dogs and pigs as reservoir for zoonotic transmission.
Read the detailed description

Primary objective:

Following obtaining informed consent, schoolchildren in the target age range group will be recruited and asked to provide a recent stool sample (an interval of less than 4 hours) that will be processed to determine the Faecal Egg Count (FEC) for each Soil-Transmitted Helminths (STH) present. For the initial sampling the aim is to enroll at least 250 infected children for at least one of the Soil-Transmitted Helminths (STH). This sample size was selected based on statistical analysis of study power, using random simulations of correlated over-dispersed Faecal Egg Count data reflecting the variance-covariance structure in a selection of real Faecal Egg Count (FEC) data sets. This analysis suggested that a sample size of up to 200 individuals (α = 0.05, power = 80%) was required to detect a 10 percentage point drop from a null efficacy of ~ 80% (mean percentage FEC ∆ per individual) over a wide range of infection scenarios. Standard power analyses for proportions also indicated that the detection of a ~10 percentage point drop from a null cure rate required sample sizes up to 200 (the largest samples being required to detect departures from null efficacies of around 50%). Given an anticipated non-compliance rate of 25%, a sample of 250 infected subjects was therefore considered necessary at each study site.

All children providing stool samples will be treated with mebendazole (MBZ) single table of 500mg under supervision (chewing + water). The mebendazole (MBZ) will be provided (free) by the coordinating group. Seven up to fourteen days (maximum interval) after treatment a second faecal sample will be collected from the children to determine again FEC. Subjects who are unable to provide a stool sample at follow-up, or who are experiencing a severe concurrent medical condition or have diarrhea at time of the first sampling, will be excluded from the study.

Secondary objectives:

In 5 study sites, faecal samples of 100 infected subjects should be preserved before treatment with mebendazole (MBZ) in one tube (1 gram in 10 ml 70% ethanol). Samples of the same children should be also preserved again in one tube (1 gram in 10 ml 70% ethanol) after treatment. Samples have be send to the Laboratory of Parasitology, Ghent University.

The samples, collected before and after treatment will be subsequently examined by molecular assays the occurrence Necator americanus/Ancylostoma duodenal and the occurrence of β-tubulin mutations related to resistance.

The samples collected before treatment will be subsequently examined by molecular assays to assess the role of animals as a reservoir for human Soil-Transmitted Helminths (STH).

Parasitological techniques, determination of Faecal Egg Count of Soil-Transmitted Helminths (STH). All fecal samples were processed using the McMaster egg counting technique for the detection and the enumeration of infections with A. lumbricoides, T. trichiura and hookworms. All study sites are familiar with the technique and McMaster slides were provided previously.

Molecular assays (Laboratory of Parasitology, Ghent University)and Deoxyribonucleic acid (DNA) extraction.

DNA of Soil-Transmitted Helminths (STH) will be extracted from the samples preserved in ethanol 70% using the Qiagen mini stool kit.

Molecular identification of Soil-Transmitted Helminths (STH). The presence of the Soil-Transmitted Helminths species: Ascaris (n= 2), Trichuris (n = 2) and hookworms (n = 4) will be assessed using different molecular assays. For the differentiation of Trichuris species, species-specific polymerase chain reaction (PCR) will be applied. For the differentiation of Ascaris and the canine hookworms a PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) will be used. For the human hookworms, a quantitative PCR will be applied.

Presence of mutations in β-tubulin related to mebendazole (MBZ) resistance This specific objective will be performed in collaboration with McGill University (Canada).

Statistical analysis. Both Cure Rate (CR) and Faecal Egg Count Reduction (FECR) will be considered to monitor to efficacy of mebendazole (MBZ) against Soil-Transmitted Helminths. The statistical analysis will be assessed as described by Vercruysse et al., 2011.

Being tested
Mebendazole
Medical subject headings
Trichuriasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MebendazoleDrug

    All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).

Study groups in NCT01379326
Study groupRoleWhat they receive
MebendazoleExperimentalNot described
Receives: Drug: Mebendazole

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Reduction of fecal egg counts at 14 days post-intervention.

    Fecal egg counts at intervention and at 14 days follow-up.

    Measured: At 14 days post-intervention.

Secondary outcomes (1)
  1. Distribution of hookworms species.

    Presence of zoonotic Soil-Transmitted Helminths species, mutations linked with anthelminthic resistance.

    Measured: Samples will be collected at 14 days of follow-up.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jun 2011 (estimated)
  2. Study startDec 2011
  3. Primary completionDec 2012
  4. Study completionDec 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
250 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01379326
Sponsor's protocol ID
2011/374
Acronym
ConWorm
Status last verified
Dec 2014
First submitted
21 Jun 2011
Last updated
5 Dec 2014
Results posted
No
Data monitoring committee
No

Publications

  • Levecke B, Montresor A, Albonico M, Ame SM, Behnke JM, Bethony JM, Noumedem CD, Engels D, Guillard B, Kotze AC, Krolewiecki AJ, McCarthy JS, Mekonnen Z, Periago MV, Sopheak H, Tchuem-Tchuente LA, Duong TT, Huong NT, Zeynudin A, Vercruysse J. Assessment of anthelmintic efficacy of mebendazole in school children in six countries where soil-transmitted helminths are endemic. PLoS Negl Trop Dis. 2014 Oct 9;8(10):e3204. doi: 10.1371/journal.pntd.0003204. eCollection 2014 Oct.

    PubMed 25299391

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Mebendazole in people with Ascaris Lumbricoides and Ascaris Suum, run by University Ghent at 9 sites in 8 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Dec 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in Australia, Argentina, Brazil, Cambodia, Cameroon and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Reduction of fecal egg counts at 14 days post-intervention. (time frame: At 14 days post-intervention.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01379326, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in